Beyond Air, Inc. (XAIR) Stock Analysis and Metrics

Sector: Healthcare Industry: Medical Devices CIK: 0001641631

Market Cap 2.53 Mn

P/E 0.04

P/S 0.37

Div. Yield 0.00

Total Debt (Qtr) 21.97 Mn

Revenue Growth (1y) (Qtr) 104.66

Add ratio to table...

About

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company that develops a nitric oxide generation and delivery platform called LungFit® capable of producing nitric oxide from ambient air. The LungFit® system can generate nitric oxide concentrations ranging from 0.5 parts per million to 400 parts per million and deliver it continuously or for a fixed amount of time at various flow rates with the ability to titrate dose on demand or maintain a constant dose. The company’s first product, LungFit® PH, received FDA premarket...

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company that develops a nitric oxide generation and delivery platform called LungFit® capable of producing nitric oxide from ambient air. The LungFit® system can generate nitric oxide concentrations ranging from 0.5 parts per million to 400 parts per million and deliver it continuously or for a fixed amount of time at various flow rates with the ability to titrate dose on demand or maintain a constant dose. The company’s first product, LungFit® PH, received FDA premarket approval in June 2022 for the treatment of persistent pulmonary hypertension of the newborn and later obtained European CE mark approval in November 2024 for additional indications in neonates, infants, children and adults undergoing heart surgery. Beyond Air also advances pipeline candidates LungFit® PRO for viral lung infections and LungFit® GO for nontuberculous mycobacterial lung disease, while exploring nitric oxide based therapies for solid tumors through its majority owned affiliate Beyond Cancer and neuronal nitric oxide synthase inhibitors for autism spectrum disorder through its affiliate NeuroNOS.

Revenue is generated primarily from the sale of LungFit® PH devices and associated disposables to hospitals and other healthcare providers. The company began marketing LungFit® PH in the United States in September 2022 and has secured distribution agreements covering France, Italy, Turkey, India, Saudi Arabia, Morocco and other regions, anticipating meaningful contribution to revenue starting in fiscal 2026. Based on internal estimates, the US sales potential for LungFit® PH in persistent pulmonary hypertension of the newborn is approximately $350 million and the worldwide sales potential is approximately $700 million or greater. Future revenue streams are expected from the commercialization of LungFit® PRO for viral lung infections, with an estimated US market potential greater than $1.5 billion and worldwide market potential greater than $3 billion, and LungFit® GO for nontuberculous mycobacterial lung disease, with an estimated US market potential greater than $1 billion and worldwide market potential greater than $2.5 billion. Additionally, the company expects to receive royalties and milestone payments from its oncology and neurology subsidiaries and pays a low single digit royalty to NitricGen under the licensed eNOGenerator technology. Manufacturing is outsourced to contract manufacturers Spartronics LLC and Medisize Ireland Limited with finished goods staged from a central warehouse in Atlanta, Georgia.

Beyond Air competes in the nitric oxide therapy market against established players such as Mallinckrodt’s INOMAX®, Linde Group’s NOxBOX®, Air Liquide’s KINOX™, VERO Biotech’s GENOSYL DS and Bellerophon Therapeutics, which are developing NO delivery systems for various respiratory and cardiac indications. The company’s competitive advantage stems from its ability to generate nitric oxide directly from ambient air, eliminating the need for high pressure cylinders and complex purging procedures, which reduces logistical burden on hospital staff. LungFit® systems can deliver nitric oxide concentrations above 150 parts per million, enabling potential antimicrobial applications beyond vasodilation, and include an integrated monitoring system that continuously measures nitric oxide, nitrogen dioxide and inspired oxygen fractions. The device is portable and can be administered non invasive through a facial mask, making it suitable for use in intensive care units, operating rooms and outpatient settings. Beyond Air’s intellectual property portfolio includes a global exclusive license to the eNOGenerator from NitricGen and numerous issued patents and pending applications covering its NO generation, delivery and monitoring technologies.

The company serves hospitals, neonatal intensive care units, pediatric cardiology wards, adult cardiac surgery centers and pulmonary clinics that treat patients with hypoxic respiratory failure, pulmonary hypertension or severe lung infections. While specific customer names are not disclosed in the filing, the target clientele includes major medical centers and community hospitals across the United States and international markets where LungFit® PH has received regulatory clearance, including Australia, New Zealand, Hong Kong, Thailand and countries in Europe, the Middle East and Asia served through distribution agreements with partners such as Getz Healthcare, and direct agreements covering France, Italy, Turkey, India, Saudi Arabia and Morocco. Beyond Air markets its products directly through a field sales team and provides necessary training via a separate team of clinical specialists.

Investment thesis

Bull case

Beyond Air’s first‑generation LungFit PH platform has achieved double‑digit revenue growth, doubling year‑over‑year to $2.2 million, while maintaining a 90%+ customer retention rate and securing over 45 hospital installations globally. The company’s aggressive cost discipline has trimmed operating expenses by more than a third, with SG&A and R&D reductions reflecting a leaner sales and product development structure. These financial levers translate directly into a healthier cash runway, giving management a clear pathway to sustained top‑line expansion without requiring immediate external capital beyond the recently closed $5 million equity round. The current mix of multiyear contracts and GPO agreements provides a predictable revenue base that can absorb future price increases and support margin improvement as production volumes rise.
The planned divestiture of the Neuronos subsidiary is not merely a clean‑up transaction; it represents a strategic shift that unlocks a significant milestone payment stream, potentially up to $31.5 million, while ceding a 19.9% equity stake in XTL Biopharmaceutical. This equity exposure is an added upside, as XTL’s pipeline could generate additional licensing or royalty revenue if its neuro‑oncology or autism programs succeed. The transaction therefore diversifies Beyond Air’s cash sources and reduces the company’s operational burden on the nitric oxide platform, allowing the team to focus resources on scaling Gen 2. Investors who overlook this structural realignment may miss an opportunity to capitalize on a one‑off infusion of liquidity and a long‑term equity partnership.
The U.S. Department of Veterans Affairs procurement pathway has opened a national gateway, with the first commercial sale of LungFit PH to a VA medical center. By leveraging the VA’s ECAT system, Beyond Air bypasses the typical lengthy RFP process and gains blanket access to the largest integrated health network in the country. This channel not only accelerates revenue generation but also signals institutional confidence in the product’s clinical value, which can be leveraged in future GPO negotiations and in international tender processes. The strategic advantage of VA access is a catalyst that is unlikely to be replicated by competitors without similar partnerships, thereby positioning Beyond Air ahead of peers in the nitric oxide device market.
International expansion has moved from a pipeline to reality, with distribution agreements spanning 40 countries, including Canada, Germany, Brazil, Austria, the Netherlands, and Sri Lanka. Repeat accessory orders from these partners demonstrate product stickiness and hint at a growing ecosystem of consumables, which are high‑margin revenue drivers. The diversified geographic footprint reduces concentration risk and exposes the company to emerging markets where lung disease prevalence is rising, potentially creating a new growth engine that is currently underappreciated by the market. Furthermore, the ability to serve global customers without a significant increase in fixed costs enhances scalability and supports a higher top‑line trajectory as Gen 2 gains regulatory clearance worldwide.
Management’s confidence in a Gen 2 approval before the end of 2026 is backed by consistent FDA communication and the completion of contract manufacturer inspections, which are the primary regulatory gatekeepers. Even though the company remains in the pre‑approval stage, the transparency in its regulatory strategy indicates a clear, manageable path to market entry. Once approved, Gen 2 will offer a 3,000‑hour service interval—three times longer than the first generation—thereby reducing maintenance costs for hospitals and improving operating margins. The combined effect of higher price potential and lower service frequency creates a strong value proposition that can be priced to reflect premium performance, further accelerating profitability.

Beyond Air’s first‑generation LungFit PH platform has achieved double‑digit revenue growth, doubling year‑over‑year to $2.2 million, while maintaining a 90%+ customer retention rate and securing over 45 hospital installations globally. The company’s aggressive cost discipline has trimmed operating expenses by more than a third, with SG&A and R&D reductions reflecting a leaner sales and product development structure. These financial levers translate directly into a healthier cash runway, giving management a clear pathway to sustained top‑line expansion without requiring immediate external capital beyond the recently closed $5 million equity round. The current mix of multiyear contracts and GPO agreements provides a predictable revenue base that can absorb future price increases and support margin improvement as production volumes rise.
The planned divestiture of the Neuronos subsidiary is not merely a clean‑up transaction; it represents a strategic shift that unlocks a significant milestone payment stream, potentially up to $31.5 million, while ceding a 19.9% equity stake in XTL Biopharmaceutical. This equity exposure is an added upside, as XTL’s pipeline could generate additional licensing or royalty revenue if its neuro‑oncology or autism programs succeed. The transaction therefore diversifies Beyond Air’s cash sources and reduces the company’s operational burden on the nitric oxide platform, allowing the team to focus resources on scaling Gen 2. Investors who overlook this structural realignment may miss an opportunity to capitalize on a one‑off infusion of liquidity and a long‑term equity partnership.
The U.S. Department of Veterans Affairs procurement pathway has opened a national gateway, with the first commercial sale of LungFit PH to a VA medical center. By leveraging the VA’s ECAT system, Beyond Air bypasses the typical lengthy RFP process and gains blanket access to the largest integrated health network in the country. This channel not only accelerates revenue generation but also signals institutional confidence in the product’s clinical value, which can be leveraged in future GPO negotiations and in international tender processes. The strategic advantage of VA access is a catalyst that is unlikely to be replicated by competitors without similar partnerships, thereby positioning Beyond Air ahead of peers in the nitric oxide device market.
International expansion has moved from a pipeline to reality, with distribution agreements spanning 40 countries, including Canada, Germany, Brazil, Austria, the Netherlands, and Sri Lanka. Repeat accessory orders from these partners demonstrate product stickiness and hint at a growing ecosystem of consumables, which are high‑margin revenue drivers. The diversified geographic footprint reduces concentration risk and exposes the company to emerging markets where lung disease prevalence is rising, potentially creating a new growth engine that is currently underappreciated by the market. Furthermore, the ability to serve global customers without a significant increase in fixed costs enhances scalability and supports a higher top‑line trajectory as Gen 2 gains regulatory clearance worldwide.
Management’s confidence in a Gen 2 approval before the end of 2026 is backed by consistent FDA communication and the completion of contract manufacturer inspections, which are the primary regulatory gatekeepers. Even though the company remains in the pre‑approval stage, the transparency in its regulatory strategy indicates a clear, manageable path to market entry. Once approved, Gen 2 will offer a 3,000‑hour service interval—three times longer than the first generation—thereby reducing maintenance costs for hospitals and improving operating margins. The combined effect of higher price potential and lower service frequency creates a strong value proposition that can be priced to reflect premium performance, further accelerating profitability.

Bear case

The core uncertainty surrounding the Gen 2 approval remains a substantial risk, as the product is still dependent on contract manufacturer inspections and FDA clearance. While management frames the timeline as “fairly constant,” there is no guarantee that regulatory reviews will not encounter unforeseen technical or safety objections, which could delay market entry by months or even years. Such a delay would compress the projected revenue ramp, extend the cash burn period, and potentially erode investor confidence, especially in a sector where timing is critical to capturing market share from established players.
Production scaling for Gen 2 presents a hidden operational hurdle; the company’s current COGS projections of 60–70% rely heavily on achieving economies of scale that may be difficult to realize given the device’s complex assembly and reliance on a single contract manufacturer. If the manufacturer experiences capacity constraints or cost overruns, the gross margin could suffer, and the anticipated 70% margin target may become unattainable. Such margin compression would directly impact the company’s path to profitability and could force additional capital raises, diluting existing shareholders.
Beyond Air’s product portfolio is narrowly focused on a single nitric‑oxide delivery platform. This concentration exposes the company to industry disruption from alternative oxygen therapies or new technologies that could render the device obsolete. While the company emphasizes the market potential for nitric oxide, competitors could introduce lower‑cost or higher‑efficiency alternatives, eroding market share. The company’s lack of diversification means that any technological shift or adverse regulatory developments could disproportionately impact its revenue base.
The company’s cash runway, while extended to 2027, is still relatively short in the context of medical device commercialization, where multi‑year development and market entry cycles are common. Management’s optimistic projection that cash resources will support profitability depends on hitting current revenue estimates and controlling costs, yet the company has not yet demonstrated sustained profitability at any point. Any deviation from the projected sales trajectory could force the company to seek additional financing, potentially at unfavorable terms, or to delay Gen 2 launch, thereby increasing the risk of market entry failure.
The reliance on a limited number of high‑profile customers, such as the VA and a few GPOs, introduces concentration risk; if any of these key contracts are renegotiated, reduced, or lost, the company could experience a significant revenue hit. While the company has 45 hospital installations, the market penetration is still nascent, and the majority of sales are derived from a small set of repeat buyers. A loss of even one large customer could disproportionately affect revenue and investor sentiment.

The core uncertainty surrounding the Gen 2 approval remains a substantial risk, as the product is still dependent on contract manufacturer inspections and FDA clearance. While management frames the timeline as “fairly constant,” there is no guarantee that regulatory reviews will not encounter unforeseen technical or safety objections, which could delay market entry by months or even years. Such a delay would compress the projected revenue ramp, extend the cash burn period, and potentially erode investor confidence, especially in a sector where timing is critical to capturing market share from established players.
Production scaling for Gen 2 presents a hidden operational hurdle; the company’s current COGS projections of 60–70% rely heavily on achieving economies of scale that may be difficult to realize given the device’s complex assembly and reliance on a single contract manufacturer. If the manufacturer experiences capacity constraints or cost overruns, the gross margin could suffer, and the anticipated 70% margin target may become unattainable. Such margin compression would directly impact the company’s path to profitability and could force additional capital raises, diluting existing shareholders.
Beyond Air’s product portfolio is narrowly focused on a single nitric‑oxide delivery platform. This concentration exposes the company to industry disruption from alternative oxygen therapies or new technologies that could render the device obsolete. While the company emphasizes the market potential for nitric oxide, competitors could introduce lower‑cost or higher‑efficiency alternatives, eroding market share. The company’s lack of diversification means that any technological shift or adverse regulatory developments could disproportionately impact its revenue base.
The company’s cash runway, while extended to 2027, is still relatively short in the context of medical device commercialization, where multi‑year development and market entry cycles are common. Management’s optimistic projection that cash resources will support profitability depends on hitting current revenue estimates and controlling costs, yet the company has not yet demonstrated sustained profitability at any point. Any deviation from the projected sales trajectory could force the company to seek additional financing, potentially at unfavorable terms, or to delay Gen 2 launch, thereby increasing the risk of market entry failure.
The reliance on a limited number of high‑profile customers, such as the VA and a few GPOs, introduces concentration risk; if any of these key contracts are renegotiated, reduced, or lost, the company could experience a significant revenue hit. While the company has 45 hospital installations, the market penetration is still nascent, and the majority of sales are derived from a small set of repeat buyers. A loss of even one large customer could disproportionately affect revenue and investor sentiment.

Award Type Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	154.42 Bn	24.69	3.42	34.05 Bn
2	SYK	Stryker Corp	118.12 Bn	35.34	4.67	14.72 Bn
3	MDT	Medtronic plc	101.72 Bn	22.04	2.87	28.07 Bn
4	BSX	Boston Scientific Corp	67.19 Bn	18.78	3.26	11.03 Bn
5	EW	Edwards Lifesciences Corp	50.69 Bn	47.57	8.04	0.60 Bn
6	PHG	Koninklijke Philips Nv	29.38 Bn	-0.02	1.46	9.48 Bn
7	DXCM	Dexcom Inc	28.09 Bn	30.39	5.83	-
8	GEHC	GE HealthCare Technologies Inc.	28.08 Bn	14.73	1.34	10.13 Bn

Research Tools

Developers

Beyond Air, Inc. (NASDAQ: XAIR)

About

Investment thesis

Bull case

Bear case

Award Type Breakdown of Revenue (2025)

Award Type Breakdown of Revenue (2025)

Peer comparison

Research Tools

Developers

Beyond Air, Inc. (NASDAQ: XAIR)

About

Investment thesis

Bull case

Bear case

Award Type Breakdown of Revenue (2025)

Award Type Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password